Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $166,846.68 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 36,036 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $4.63, for a total value of $166,846.68. Following the completion of the sale, the chief financial officer now owns 263,190 shares in the company, valued at $1,218,569.70. The trade was a 12.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, January 30th, Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total value of $91,896.22.
• On Friday, December 27th, Thomas Catinazzo sold 4,865 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.42, for a total transaction of $21,503.30.

Relay Therapeutics Trading Up 1.3 %

Shares of NASDAQ RLAY traded up $0.06 during trading hours on Thursday, hitting $4.54. 1,154,019 shares of the company traded hands, compared to its average volume of 2,957,148. The company’s 50 day moving average price is $4.53 and its 200 day moving average price is $6.12. Relay Therapeutics, Inc. has a 12 month low of $3.50 and a 12 month high of $11.16. The stock has a market capitalization of $759.92 million, a price-to-earnings ratio of -1.74 and a beta of 1.60.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.14. Relay Therapeutics’s quarterly revenue was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. Equities analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RLAY. Leerink Partners dropped their price target on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Relay Therapeutics in a research report on Tuesday, January 14th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price objective on shares of Relay Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Institutional Trading of Relay Therapeutics

Hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in Relay Therapeutics by 6.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company’s stock worth $292,000 after purchasing an additional 2,547 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Relay Therapeutics in the 3rd quarter worth about $63,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Relay Therapeutics by 37.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company’s stock worth $146,000 after acquiring an additional 9,740 shares during the last quarter. Portland Investment Counsel Inc. purchased a new stake in shares of Relay Therapeutics during the third quarter worth approximately $71,000. Finally, XTX Topco Ltd lifted its holdings in Relay Therapeutics by 27.9% in the 3rd quarter. XTX Topco Ltd now owns 47,271 shares of the company’s stock valued at $335,000 after purchasing an additional 10,311 shares in the last quarter. 96.98% of the stock is owned by hedge funds and other institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.